Skip to main content

Advertisement

Table 1 Association between the study variables and the emergence of HIV-1 drug resistance

From: Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana

Study variables HIV drug resistance P value
DRAMs, N (%) No DRAMs, N (%) Total N (%)
Study groups 1 (ART with prophylaxis) 8(32) 17(68) 25(21.6) .002a
2 (Drug-Naïve) 4(15) 22(85) 26(22.4)
3 (ART with no prophylaxis) 3(5) 62(95) 65(56.0)
Duration on art (Groups 1 & 3) <  1 Year 4(16.7) 20(83.3) 24(26.7) .624a
1-2 Years 5(12.5) 35(87.5) 40(44.4)
≥ 3 Years 2(7.7) 24(92.3) 26(28.9)
Who clinical staging 1 9(23.7) 29(76.3) 38(32.8) .113a
2 4(8.3) 44(91.7) 48(41.4)
3 2(7.1) 26(92.9) 28(24.1)
4 0(0) 2(100) 2(1.7)
Adherence Yes 10 (12.0) 73 (88.0) 83(92.2) .560a
No 1 (14.3) 6 (85.7) 7(7.8)
  1. a Significant at 5%